The Sp1/Egr1-tandem repeat polymorphism in the 5-lipoxygenase gene promoter is not associated with late onset Alzheimer disease

Alzheimer Disease and Associated Disorders

Volumn 22, Issue 2, 2008, Pages 177-180

  Alvarez, Victoria ^a   González, Pelayo ^a   Corao, Ana I ^a   Menéndez, Manuel ^b,c   Lahoz, Carlos H ^b   Martínez, Carmen ^d   Calatayud, Maite ^b   Morales, Blanca ^a   Coto, Eliecer ^a,b  

^a Genetica Molecular   (Spain)

^b HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^c Hospital A Buylla   (Spain)

^d HOSPITAL DE CABUEÑES   (Spain)

Author keywords

Alzheimer disease; Arachidonate 5 lipoxygenase; Gene polymorphism; Genetic association

Indexed keywords

APOLIPOPROTEIN E; ARACHIDONATE 5 LIPOXYGENASE; EARLY GROWTH RESPONSE FACTOR 1; ETANIDAZOLE; EGR1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR SP1;

ADULT; AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN MOTIF; TANDEM REPEAT; CASE CONTROL STUDY; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; SPAIN;

AGE OF ONSET; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; APOLIPOPROTEINS E; ARACHIDONATE 5-LIPOXYGENASE; CASE-CONTROL STUDIES; EARLY GROWTH RESPONSE PROTEIN 1; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); SP1 TRANSCRIPTION FACTOR; SPAIN; TANDEM REPEAT SEQUENCES;

EID: 46249093149     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/WAD.0b013e3181572046     Document Type: Article

References (29)

1. Silverman ES, Drazen JM. The biology of 5-lipoxygenase: function, structure, and regulatory mechanisms. Proc Assoc Am Physicians. 1999;111:525-536.
2. Goulet JL, Snouwaert JN, Latour AM, et al. Altered inflammatory responses in leukotriene-deficient mice. Proc Natl Acad Sci USA. 1994;91:12852-12856.
3. Henderson WR Jr. The role of leukotrienes in inflammation. Ann Intern Med. 1994;121:684-697.
4. Zlokovic BV. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci. 2005;28:202-208.
5. Stuchbury G, Munch G. Alzheimer's associated inflammation, potential drug targets and future therapies. LJ Neural Transm. 2005;112:429-453.
6. Ikonomovic MD, Abrahamson EE, Manev H, et al. 5-lipoxygenase protein is elevated in the hippocampus of Alzheimer's disease patients. Neurobiol Aging. 2004;25(suppl 2):S435.
7. Manev H, Manev R. 5-lipoxygenase (ALOX5) and FLAP (ALOX5AP) gene polymorphisms as factors in vascular pathology and Alzheimer's disease. Med Hypoth. 2006;66:501-503.
8. Qu T, Manev R, Manev H. 5-lipoxygenase (5-LOX) promoter polymorphism in patients with early and late-onset Alzheimer's disease. J Neuropsychiatry Clin Neurosci. 2001;13:304-305.
9. In KH, Asano K, Beier D, et al. Naturally occurring mutations in the human 5-lipoxygensase gene promoter that modify transcription factor binding and reporter gene transcription. J Clin Invest. 1997; 99:1130-1137.
10. Dwyer JH, Allayee H, Dwyer KM, et al. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N Engl J Med. 2004;350:29-37.
11. Drazen JM, Yandava CN, Dube L, et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet. 1999;22:168-170.
12. Kalayci O, Birben E, Sackesen C, et al. ALOX5 promoter genotype, asthma severity and LTC production by eosinophils. Allergy. 2006; 61:97-103.
13. Wenham PR, Price WH, Blundell G. Apolipoprotein E genotyping by one-stage PCR. Lancet. 1991;337:1158-1159.
14. Chen XS, Sheller JR, Johnson EN, et al. Role of leukotrienes revealed by targeted disruption of the 5-lipoxygenase gene. Nature. 1994;372:179-182.
15. Fowler SJ, Hall IP, Wilson AM, et al. 5-lipoxygenase polymorphism and in-vivo response to leukotriene receptor antagonists. Eur J Clin Pharmacol. 2002;58:187-190.
16. Helgadottir A, Manolescu A, Thorleifsson G, et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infraction and stroke. Nat Genet. 2004;36:233-239.
17. Helgadottir A, Manolescu A, Helgason A, et al. A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat Genet. 2006;38:68-74.
18. Cipollone F, Mezzetti A, Fazia ML, et al. Association between 5-lipoxygenase expression and plaque instability in humans. Art Thromb Vasc Biol. 2005;25:1665-1670.
19. Silverman ES, Drazen JM. Genetic variations in the 5-lipoxygenase core promoter: description and functional implications. Am J Respir Crit Care Med. 2000;161:S77-S80.
20. Gonzalez P, Reguero JR, Lozano I, et al. A functional Sp1/Egr1-tandem repeat polymorphism in the 5-lipoxygenase gene is not associated with myocardial infarction. Int J Immunogenet. 2007;34: 127-130.
21. Bertram L, Tanzi RE. The genetic epidemiology of neurodegenerative disease. J Clin Invest. 2005;115:1449-1457.
22. Tanzi RE, Bertram L. New frontiers in Alzheimer's disease genetics. Neuron. 2001;32:181-184.
23. Mayeux R, Sano M, Chen J, et al. Risk of dementia in first-degree relatives of patients with Alzheimer's disease and related disorders. Arch Neurol. 1991;48:269-273.
24. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high activity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA. 1993;90:1977-1981.
25. Schmechel DE, Saunders AM, Strittmatter WJ, et al. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in lateonset Alzheimer disease. Proc Natl Acad Sci USA. 1993;90: 1977-1981.
26. Alvarez V, Alvarez R, Pena J, et al. Frequency of the APOE-4 allele in Alzheimer's disease and its variation with age in Asturias (Spain). Med Clin (Barc). 1999;113:441-443.
27. Rasmusson DX, Brandt J, Steele C, et al. Accuracy of clinical diagnosis of Alzheimer disease and clinical features of patients with non-Alzheimer disease neuropathology. Alzheimer Dis Assoc Disord. 1996;10:180-188.
28. Honig LS, Kukull W, Mayeux R. Atherosclerosis and AD. Analysis of data from the US National Alzheimer's Coordinating Center. Neurology. 2005;64:494-500.
29. Kosunen O, Talasniemi S, Lehtovirta M, et al. Relation of coronary atherosclerosis and apolipoprotein E genotypes in Alzheimer patients. Stroke. 1995;26:743-748.